Increased propensity for calcium phosphate kidney stones with topiramate use.

@article{Vega2007IncreasedPF,
  title={Increased propensity for calcium phosphate kidney stones with topiramate use.},
  author={Damaris Vega and Naim M. Maalouf and Khashayar Sakhaee},
  journal={Expert opinion on drug safety},
  year={2007},
  volume={6 5},
  pages={547-57}
}
Topiramate (TPM) is a neuromodulatory agent that was initially approved as an antiepileptic drug and is increasingly used in the treatment of a number of neurological and metabolic disorders. Among its various pharmacological actions, TPM has been shown to inhibit the activity of specific carbonic anhydrase enzymes in the kidney. This action is associated with the development of metabolic acidosis, hypocitraturia, hypercalciuria and elevated urine pH, leading to an increased risk of kidney… CONTINUE READING
17 Citations
0 References
Similar Papers

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…